1.        Developing strategies for efficient and sequence-specific DNA modifying agents. Site specific cleavage of RNA and DNA will be sought by developing novel chemical nucleases and PDT-directed cleavage agents, respectively.

2.        PNA based molecular beacons

3.     siRNA delivery

4.        Chemically stabilized siRNA for improved gene silencing.

5.        Developing site-specific anti-cancer agents to the mitochondria.

Current projects include:

1. Photo-dynamic therapy based on anti-gene recognition: Developing DNA-dye conjugates for the direct and site-specific photocleavage of DNA.

2. Chemical nucleases based on a cyclic peptide scaffold.

3. The synthesis of novel PNA based MB's for early diagnosis of colorectal cancer.

4. Improved stability and delivery of siRNA for efficient gene regulation.

5. Anti-cancer agents targeted to mitochondria.

Active collaborations include:

Prof. Israel Ringel on the development of anti-cancer agents targeting the mitochondria.
Prof. Chezy Barenholz on siRNA delivery based on modified peptides.

Profs. Simon Benita and Philip Lazarovici on siRNA delivery based on nano-encapsulated NP's.

Prof. Avri Rubinstein on the development of PNA based molecular beacons. 

Prof. Joshua Katzhendler on the development of novel PNA's.